Pharma BD Deal Intelligence
Amgen picked up Otezla for $13.4B out of the forced Celgene divestiture required to clear Bristol-Myers Squibb's takeover—a rare case of an FTC-mandated sale becoming a genuine strategic win. The deal gave Amgen its first blockbuster inflammation asset outside biologics, a franchise anchor rather than a fire-sale afterthought.
Amgen acquired Otezla (apremilast) for $13.4B from Celgene psoriasis drug divestiture.
Amgen Q3 2025 results: recorded a $400M Otezla intangible-asset impairment charge, reflecting Otezla performance below the long-term acquisition plan.
Amgen Q4/FY2025 results: Otezla full-year sales $2,265M, up 7% YoY (FY2024 $2,126M), driven by volume growth and favorable sales deductions.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Amgen acquired Otezla (apremilast) for $13.4B from Celgene psoriasis drug divestiture.
Otezla (apremilast), an oral PDE4 inhibitor, received FDA approval July 2019 for oral ulcers associated with Behcet's disease, the first and only FDA-approved treatment for this manifestation; it therefore faces no MOA-matched direct competitor. The off-label and adjunct competitive landscape groups into four MOA classes. Topical/local corticosteroids and colchicine (standard first-line for mucocutaneous Behcet per EULAR 2018 recommendations): triamcinolone acetonide dental paste, clobetasol gel (generic), dexamethasone mouth rinse, and oral colchicine (generic) are widely used but lack FDA Behcet-specific labeling. Systemic corticosteroids and conventional DMARDs (moderate-severe or multi-organ disease): prednisone (generic), azathioprine (Imuran/generic), cyclosporine (Sandimmune/Neoral, generic), methotrexate (generic). TNF-alpha inhibitors (off-label, severe/refractory Behcet with uveitis or vascular involvement): adalimumab (Humira, AbbVie; biosimilars Amjevita, Hyrimoz, Yuflyma), infliximab (Remicade, Janssen; biosimilars Inflectra, Renflexis, Avsola), and etanercept (Enbrel, Amgen). IL-1 and IL-6 inhibitors (small trials, refractory disease): anakinra (Kineret, SOBI), canakinumab (Ilaris, Novartis), tocilizumab (Actemra, Roche). Interferon alpha-2a (historical, declining use). Otezla's Behcet oral-ulcer exclusivity is a defensible orphan-like niche; the primary franchise threat is anti-TNF usage in patients requiring multi-organ control. Source: FDA Otezla Behcet approval letter.
Otezla (apremilast), oral PDE4 inhibitor approved for psoriatic arthritis (PsA) in 2014, competes in a PsA market structured around six MOA classes with biologics dominating moderate-severe disease. TNF-alpha inhibitors (first-line biologic per ACR/NPF 2018 guidelines): adalimumab (Humira, AbbVie and biosimilars including Amjevita, Cyltezo, Hyrimoz, Yuflyma), etanercept (Enbrel, Amgen), infliximab (Remicade/biosimilars), golimumab (Simponi/Simponi Aria, J&J), certolizumab (Cimzia, UCB). IL-17 inhibitors: secukinumab (Cosentyx, Novartis, FY2023 sales $5.3B per Novartis 20-F), ixekizumab (Taltz, Lilly), bimekizumab (Bimzelx, UCB, FDA approved for PsA September 2024). IL-23 p19 inhibitors: guselkumab (Tremfya, J&J, FDA approved for PsA 2020), risankizumab (Skyrizi, AbbVie, FDA approved for PsA 2022). IL-12/23 inhibitor: ustekinumab (Stelara, J&J; biosimilars 2025). JAK inhibitors (oral, direct competitor to Otezla's oral slot): tofacitinib (Xeljanz, Pfizer), upadacitinib (Rinvoq, AbbVie). Conventional synthetic DMARDs (first-line for peripheral arthritis): methotrexate (generic), sulfasalazine (generic), leflunomide (Arava/generic). T-cell costimulation blocker: abatacept (Orencia, BMS). Rinvoq, Skyrizi, and Tremfya represent the primary franchise threats; Otezla's positioning as oral, non-immunosuppressive, no-lab-monitoring option preserves its moderate-disease slot. Source: FDA Rinvoq PsA approval letter.
Otezla (apremilast), the only oral PDE4 inhibitor approved for plaque psoriasis, competes in a crowded moderate-to-severe psoriasis market dominated by biologics across five MOA classes. IL-23 p19 inhibitors (current biologic standard-of-care, highest PASI-90 response rates): risankizumab (Skyrizi, AbbVie, FY2023 sales $7.8B per AbbVie 10-K), guselkumab (Tremfya, J&J, ~$3.1B), tildrakizumab (Ilumya, Sun Pharma); this class is displacing TNF and IL-17 share. IL-17 inhibitors: secukinumab (Cosentyx, Novartis, ~$5.3B FY2023), ixekizumab (Taltz, Lilly), brodalumab (Siliq, Ortho Dermatologics), bimekizumab (Bimzelx, UCB, FDA approved October 2023, dual IL-17A/F). TNF-alpha inhibitors: adalimumab (Humira, AbbVie and biosimilars since 2023), etanercept (Enbrel, Amgen), infliximab (Remicade/biosimilars), certolizumab (Cimzia, UCB). IL-12/23 inhibitor: ustekinumab (Stelara, J&J, biosimilars launched 2025). Oral small molecules (Otezla's direct MOA-adjacent class): deucravacitinib (Sotyktu, BMS), a TYK2 inhibitor approved September 2022, is the most direct oral competitor with superior PASI-75 response vs. apremilast in head-to-head POETYK PSO-1/2 (NEJM 2022). Topical non-steroidals: tapinarof (Vtama, Dermavant), roflumilast (Zoryve, Arcutis). Skyrizi and Sotyktu represent the primary franchise threat to Otezla's oral slot. Source: BMS 2023 Form 10-K Sotyktu disclosure.
Amgen closed acquisition of Otezla (apremilast) from Celgene/BMS for $13.4B cash, part of BMS-Celgene merger divestiture.
Otezla generated ~$547M in Q3 2020. Amgen projected low double-digit sales growth over five years.
Otezla generated $2.19B in FY2023, down from $2.23B in 2022, facing IL-23 and TYK2 competition.
Otezla FY2024 revenue declined to $2.13B as competitive erosion from newer biologics intensified.
Amgen recorded $400M intangible asset impairment on Otezla, confirming underperformance vs growth expectations.
Amgen reported full-year 2025 Otezla sales of $2,265M, up 7% YoY (vs $2,126M in FY2024), driven by 3% volume growth and favorable changes to estimated sales deductions. The rebound follows a $400M Otezla intangible-asset impairment Amgen recorded in Q3 2025, underscoring that the asset, while growing again, continues to track below the long-term plan that supported the $13.4B 2019 purchase price.
Otezla generated ~$2.1-2.3B annually but missed projected double-digit growth. $400M impairment confirms underperformance vs $13.4B price.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Otezla (from Celgene/BMS) (this deal) | 2019 | $13.4B | 68 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / BeiGene Ltd. | 2020 | $2.8B | 68 |
← Browse all deals · How we score deals
More: 2019 deals · Amgen Inc. deals · Dermatology deals